Issue Date: December 21, 2009
Cubist Seeks Calixa In Antibiotic Push
Cubist Pharmaceuticals has agreed to acquire privately held Calixa Therapeutics for $92.5 million in cash plus potential payments of up to $310 million, depending on the performance of CXA-201, Calixa’s lead compound. CXA-201 is a combination of CXA-101 and the β-lactamase inhibitor tazobactam. CXA-101 is a novel cephalosporin antibiotic now in Phase II trials. Both CXA-201 and CXA-101 are targeted at serious gram-negative infections. Cubist already markets daptomycin, the first in a new class of antibiotics called lipopeptides.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society